A Randomized comparative clinical study to evaluate the efficacy of vedanasthapana anal suppository and vedanasthapana taila matrabasti in the management of kashtartava (Primary dysmenorrhea)

A Randomized comparative clinical study to evaluate the efficacy of vedanasthapana anal suppository and vedanasthapana taila matrabasti in the management of kashtartava (Primary dysmenorrhea) - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055586

Enrollment

100

Registered

2023-07-24

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: i. Patients with chief complaint of lower abdomen pain during menstruation with regular cycle (21-35 days) with VAS score more than 4. ii. Age groups between 18 to 30 years shall be selected. iii. Patients suffering from dysmenorrhea for at least 3 cycles in last 6 months. iv. Married and unmarried women will be incorporated for the study. v. Patients fit for matrabasti and suppository use.

Exclusion criteria

Exclusion criteria: i. Any space occupying lesion. ii. Women with Irregular menstrual cycles. iii. Secondary dysmenorrhea. iv. IUCD v. Women diagnosed with congenital anomalies of reproductive tract. vi. Systemic or metabolic disorders which can be contraindicated for matrabasti or suppository use.

Design outcomes

Primary

Measure	Time frame
Evaluate the efficacy of vedanastapana anal suppository and vedanasthapana taila matrabasti in the management of kashtartava(primary dysmenorrhea)Timepoint: baseline, consecutive 4 menstrual cycles for 4 months	—

Secondary

Measure	Time frame
Evaluate the efficacy of vedanastapana anal suppository & vedanasthapana taila matrabasti in the management of kashtartava (primary dysmenorrhea) & in consecutive cycles after 2 months of treatmentTimepoint: consecutive 2 menstrual cycles after 2 cycles of treatment	—

Countries

India

Contacts

Public ContactDr Sangeeta Hemant Toshikhane

Parul Institute of Ayurved

drsangeetaj@gmail.com9964596479

Outcome results